Development of constrained tamoxifen mimics and their antiproliferative properties against breast cancer cells.

Bioorg Med Chem Lett

Medicinal Chemistry and Pharmacology Division, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India; Academy for Scientific Innovation and Research, New Delhi 110001, India. Electronic address:

Published: February 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

An efficient synthesis of a new series of tamoxifen mimics is described by employing iodine catalyzed ipsocyclization strategy followed by Suzuki coupling. A molecular docking studies of the synthesized compounds 11a-n and 12 in estrogen receptor (ER-α) showed that the scaffolds are fitting well in the groove, thereby suggesting them as promising antiproliferative agents for estrogen dependent breast cancer lines. All compounds were tested in vitro against breast cancer cell lines-ER positive, MCF-7; ER negative, MDA-MB-231; and control mammary epithelial cells, MEpiC. The biological results showed that most of the compounds are active against MCF-7 with IC50 values less than 6.5μM which corroborate the results of molecular docking studies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2014.11.077DOI Listing

Publication Analysis

Top Keywords

breast cancer
12
tamoxifen mimics
8
molecular docking
8
docking studies
8
development constrained
4
constrained tamoxifen
4
mimics antiproliferative
4
antiproliferative properties
4
properties breast
4
cancer cells
4

Similar Publications

Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.

View Article and Find Full Text PDF

Background: Iron metabolism may influence breast cancer development; however, links between iron-related biomarkers and breast cancer remain inconclusive. Given differences in iron status by menopausal status, we examined associations of ferritin and other iron biomarkers, with breast cancer incidence, stratified by menopausal status, in a Korean screening cohort.

Methods: This cohort study included 140,747 Korean women screened for breast cancer from 2011-2020.

View Article and Find Full Text PDF

Background: Alcohol consumption is a risk factor for certain cancers and is increasing in the United States. We estimated the impact of alcohol consumption on cancer incidence trends in the United States from 2008-2019 across six alcohol-related cancers among men and women.

Methods: Average daily alcohol consumption (ADC) was calculated from the National Health Interview Survey (NHIS, 1998-2009) and adjusted to per capita sales data to account for underreporting alcohol use.

View Article and Find Full Text PDF

Hormonal receptor status and lymph nodes involvement in breast cancer: a retrospective study.

Cell Mol Biol (Noisy-le-grand)

September 2025

Assistant Professor of General Surgery, Department of Surgery, College of Medicine, University of Duhok, Kurdistan Region, Iraq.

Hormonal status and lymphatic invasion are two important prognostic factors among cases of breast cancer. This study aims to assess and evaluate the hormonal receptor status and lymph node involvement among female breast cancer patients in Duhok city, Kurdistan region, Iraq. A retrospective cross-sectional study was conducted, involving 156 diagnosed cases of breast cancer who had undergone surgical treatment and laboratory investigations at Azadi Teaching Hospital and Duhok Private Hospital for 30 months.

View Article and Find Full Text PDF

Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.

View Article and Find Full Text PDF